This was good enough for making GMO corn but not enough for human medicine. So when, in 2012, Jennifer Doudna and Emmanuelle Charpentier discovered CRISPR-Cas9, a lot of hopes grew. This is because ...

The largest transaction of the day involved the sale of CRISPR Therapeutics AG (NASDAQ:CRSP), with ARK’s flagship ARKK ETF offloading 92,782 shares, resulting in a total dollar value of $3,514,582.

From a translational perspective, the results from this first-in-human clinical trial have important implications, because they underline the feasibility of using CRISPR-Cas9-engineered TILs in ...

Power in either model comes from a permanent-magnet synchronous motor with hairpin winding and combined water and oil cooling. It sits in a sprung subframe surrounded by stamped trailing arms and ...

The CRISPR biotech is now shelving the autoimmune program and slashing staff in order to focus its resources and its finances on the two lead cancer programs, whose data readouts have been delayed ...

In the latest market close, CRISPR Therapeutics AG (CRSP) reached $39.11, with a +1.48% movement compared to the previous day. This move lagged the S&P 500's daily gain of 2.03%. At the same time ...

Collaborating with CRISPR-Cas9 co-inventor Jennifer Doudna and Jill Banfield at UC Berkeley, Steven Jacobsen, a distinguished professor of molecular, cell and developmental biology at UCLA ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly ...